Form 4: EyePoint Pharmaceuticals CFO George Elston Reports Stock Transactions

Chief Financial Officer of EyePoint Pharmaceuticals, George Elston, reports acquisition and disposal of company stock and restricted stock units.

Summary

• On May 25, 2024, George Elston, the CFO of EyePoint Pharmaceuticals, engaged in transactions involving the company's stock and restricted stock units.
• Elston acquired 7,500 shares of common stock through the vesting of restricted stock units at a price of $0.00.
• Simultaneously, 3,627 shares were withheld by the issuer to cover tax obligations related to the vesting of the restricted stock units at a price of $11.16.
• Following these transactions, Elston directly owns 47,480 shares of common stock.
• Elston also owns 15,000 restricted stock units.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions, with neutral sentiment.

Positives

• The vesting of restricted stock units indicates a form of compensation and alignment of the CFO's interests with the company's performance.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their transactions in the company's stock.

Stakeholder Impact

• The transactions may be of interest to shareholders as they provide insight into the actions of a key executive.

Key Dates